$CDIO

Cardio Diagnostics Holdings, Inc. (CDIO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 18, 2026, Cardio Diagnostics Holdings, Inc., a Delaware corporation (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). Of the Company’s 2,959,469 shares of common stock issue

Cardio Diagnostics (CDIO) has launched an investor presentation highlighting its commercially available CHD risk tests, a CMS payment rate of $854 per test, and in-house CLIA lab operations. The company reports a 30% reduction in lab costs and 7-10 day turnaround time. Reimbursement progress includes in-network coverage and Medicare engagement.

Cardio Diagnostics (CDIO) launched its in-house, CLIA-certified lab in Iowa City, gaining full control over test processing for its Epi+Gen CHD™ and PrecisionCHD™ tests. The move is expected to improve margins to 40% at scale, reduce turnaround times, and enhance research capabilities. The company has secured licenses in several states and aims to expand its cardiovascular health monitoring system.

This article provides detailed real-time stock information for Cardio Diagnostics Holdings Inc. - Warrant (CDIOW) listed on Nasdaq. It includes current pricing, trading volume, bid/ask details, historical price ranges, and performance metrics over various periods. The content also features recent news headlines and answers frequently asked questions about the company's publicly traded status and exchange.

Cardio Diagnostics Holdings Inc. (CDIO) stocks surged by 16.09%, driven by optimistic market sentiment ahead of a strategic investor call to unveil AI-powered cardiac testing technologies. Despite current negative profitability metrics and fiscal strains, the company maintains strong liquidity. Technical analysis reveals recent volatility, with key resistance and support levels noted, and future prospects largely depend on effectively translating innovation into financial resilience and clear revenue generation.